Genomic Vision and AstraZeneca collaborate to screen WEE1 inhibitors

AstraZeneca plc (LSE:AZN; NYSE:AZN) will use the FiberVision DNA molecular combing technology from Genomic Vision S.A. (Euronext:GV) to evaluate the impact of WEE1 tyrosine kinase (WEE1) inhibitors ...